By Joseph Walker 

Medtronic Inc., which is preparing to complete a $43 billion merger with Covidien PLC, said its revenue increased 4.1% in the quarter ending in October, even as competitive pressures weighed on sales of two important product lines.

The merger, combining two of the world's largest surgical-implant and hospital-supply companies, remains on schedule to close in early 2015, Chief Executive Omar Ishrak said on a conference call with analysts. The companies plan to hold a special meeting in January to seek shareholder approval of the merger.

Medtronic's planning teams are working to ensure the company is able to reach its goal of reducing costs by a minimum of $850 million annually, before taxes, by the end of its fiscal year 2018, Mr. Ishrak said

The company is looking to reduce costs by eliminating duplicate facilities, "administrative redundancies and other back office functions, " Mr. Ishrak said.

Medtronic reported earnings of $828 million for the quarter ended Oct. 24, down 8.2% from $902 million a year earlier. Earnings per share were 83 cents, down 6.7% from 89 cents a year ago. Profit was hurt by a $100 million donation to the company's nonprofit charity organization, the Medtronic Foundation, and $61 million in costs related to the Covidien acquisition.

Excluding these charges, per-share earnings were 96 cents, compared with 91 cents a year earlier.

Revenue rose 4.1% to $4.37 billion from $4.19 billion a year earlier on the strength of sales growth in the company's pacemakers and structural heart products.

Sales of Medtronic's implanted cardiac defibrillators, or ICDs, fell 6% to $670 million, down from $713 million a year earlier. Analysts said sales were hurt by competitive pressure from Boston Scientific Corp. and St. Jude Medical Inc., rivals that have increased their market share with new product launches. Medtronic's Mr. Ishrak said the company continues to face lower selling prices for its devices, which are used to treat irregular heartbeats, amid pressure from hospital customers.

Shares of Medtronic rose 3.7% to $71.84 in midday trading on the New York Stock Exchange.

Danielle Antalffy, an analyst with Leerink Partners LLC, said in a note to clients that Medtronic's lower-than-expected ICD sales may "indicate a slightly slower recovery in one of [Medtronic's] largest businesses." The devices represent about 15% of Medtronic's total sales.

Medtronic received U.S. regulatory approval in August for a new type of defibrillator that it says reduces side effects, and which analysts expect will help the company better compete against rivals.

"The only way you mitigate that pricing pressure is to keep coming out with new products and new features that people are willing to pay for from a value perspective," Medtronic Chief Financial Officer Gary Ellis said in an interview.

Sales of Medtronic's nonsurgical heart valves, which have been one of the company's faster-growing product lines, were $131 million, unchanged from the $131 million the company reported in the first quarter of this fiscal year. Some analysts had expected sales to be as high as $160 million after competitor Edwards Lifesciences Corp. reported sequential sales growth of 21.6% in the quarter ended Sept. 30.

Mr. Ishrak attributed Edwards's growth to a recently launched heart valve in the U.S. that comes in a greater variety of sizes, which expanded the company's patient base. Edwards and Medtronic are the only companies that sell the so-called transcatheter valves in the U.S., and Mr. Ishrak estimated that Medtronic now has 40% of the U.S. market.

Medtronic's market share will increase as the company expands the number of hospitals trained in using its valves, Mr. Ellis said. Roughly 200 hospitals are trained in using Medtronic's valves, compared with 400 hospitals trained to use Edwards's valves, he said. Medtronic expects to reach 400 trained sites by next April or May, Mr. Ellis said.

Medtronic's plan to buy Covidien, based in Dublin, has drawn scrutiny over a tax tactic criticized by U.S. government officials. The acquisition plan involves Medtronic reincorporating from Minneapolis to Ireland, which would lighten the company's tax burden.

Medtronic backed its earnings outlook for the year and said revenue would grow in a range of 4% to 5%. The company had previously said it expected revenue growth of 3% to 5%.

Write to Joseph Walker at joseph.walker@wsj.com

Access Investor Kit for Covidien Plc

Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=IE00B68SQD29

Access Investor Kit for Medtronic, Inc.

Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=US5850551061

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Medtronic (NYSE:MDT)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more Medtronic Charts.
Medtronic (NYSE:MDT)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more Medtronic Charts.